Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Fate Therapeutics, Inc.

https://fatetherapeutics.com/

Latest From Fate Therapeutics, Inc.

Tech Transfer Roundup: Tonix Inks Trio Of COVID-19-Focused Deals

New York biotech is partnering with researchers at Columbia, Kansas State and Southern Research to address the pandemic.

Deals Coronavirus COVID-19

Finance Watch: Four Offerings In One Week As Biopharma Keeps Its IPO Market Lead

Lantern, Avidity, Generation Bio and Vaxcyte launched initial public offerings during the second week of June as biopharma continues to intrigue IPO investors. Also, Blackstone invested $350m in Reata's bardoxolone and Checkmate’s $85m series C led recent VC deals. 

Financing Business Strategies

J&J Spots Potential Of Fate’s Stem Cells, Signs Cancer Deal Worth Up To $3bn

Investment from Janssen helps to validate the platform developed by the San Diego-based company.

Commercial Companies

Coronavirus Update: Novartis Targets COVID-19 Cytokine Storm With Jakavi

Novartis's Jakavi joins the likes of Roche's Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients.

See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Other Names / Subsidiaries
    • Tfinity Therapeutics, Inc.
UsernamePublicRestriction

Register